Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 730.98 USD -0.28%
Market Cap: 76.8B USD

Operating Margin

27.6%
Current
Declining
by 5.3%
vs 3-y average of 32.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
27.6%
=
Operating Income
$3.9B
/
Revenue
$14.2B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
27.6%
=
Operating Income
$3.9B
/
Revenue
$14.2B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
76.2B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
977.5B USD
Loading...
US
Merck & Co Inc
NYSE:MRK
269.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
175.5B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
110.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
46.3T KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
372.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
153.8B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
No Stocks Found

Market Distribution

Higher than 88% of companies in the United States of America
Percentile
88th
Based on 14 112 companies
88th percentile
27.6%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Regeneron Pharmaceuticals Inc
Glance View

In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases. Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.

REGN Intrinsic Value
759.83 USD
Undervaluation 4%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
27.6%
=
Operating Income
$3.9B
/
Revenue
$14.2B
What is Regeneron Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Regeneron Pharmaceuticals Inc is 27.6%, which is below its 3-year median of 32.9%.

How has Operating Margin changed over time?

Over the last 3 years, Regeneron Pharmaceuticals Inc’s Operating Margin has decreased from 49.8% to 27.6%. During this period, it reached a low of 27.6% on Sep 30, 2025 and a high of 49.8% on Sep 30, 2022.

Back to Top